Our study revealed that bone marrow-derived B cells accelerate Aβ pathology and exacerbate microglial reactivity and that immune therapy targeting bone marrow-derived B cells via IL-6R blockade may benefit early AD patients. This evidence concerns the gene IL6R and Alzheimer disease.